FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297374610> ?p ?o ?g. }

• W4297374610 abstract "<h3>Purpose</h3> Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) can have many underlying causes, including inflammation (inflammatory NPSLE). Inflammatory NPSLE is rare and many aspects of inflammatory NPSLE, including treatment and treatment outcomes, remain to be elucidated. Therefore, we used clinical data from our tertiary referral centre for NPSLE to investigate inflammatory NPSLE manifestations, type of immunosuppressive treatment and clinical outcomes. <h3>Methods</h3> All patients with the clinical diagnosis of SLE visiting the LUMC NPSLE clinic between 2007–2021 that received any type of immunosuppressive therapy for NP symptoms were included. Clinical data was collected in a standardized way during a multidisciplinary evaluation at the NPSLE clinic and this information was later retrieved from patient records Patients were followed-up prospectively and clinical outcomes (short-term, 0–6 months and long-term outcomes, 7–24 months) were assessed by two independent readers and scored on a 7-point Likert scale, ranging from death to resolved. <h3>Results</h3> In a total of 101 NPSLE events in 95/398 patients (24%) visiting the NPSLE clinic, immunosuppressive treatment was initiated. The most common inflammatory NP manifestation was (severe) cognitive dysfunction (50%), often present in combination with other NPSLE manifestations (such as myelopathy and neuropathy). Interestingly, 24 patients (24%) had clear NP manifestations that are not part of the 1999 ACR case definitions for NPSLE (e.g. cerebral vasculitis and organic brain syndrome). The most common treatment modality was a combination of induction and maintenance therapy (73%), followed by solely induction therapy (24%) and other types of therapy. Nearly all patients were treated with prednisone (97%), often in combination with methylprednisolone (53%), azathioprine (49%) and cyclophosphamide (42%). Short-term outcome showed improvement on the Likert scale in 73% of patient (improved: 22%, much improved: 29%, resolved: 22%). No change was observed in 21% of patients and worsening in 6% of patients (see also Figure 1). Long-term outcome was available for 78/101 events and an improvement of the NP manifestations was seen in 70% of patients (improved:14%, much improved: 28%, resolved: 28%). No change was seen in 17% of patients, worsening in 10% and death in 3% of patients. None of the deaths were directly related to NPSLE, whereas one was potentially related to immunosuppressive treatment. <h3>Conclusion</h3> Although NPSLE is considered as one of the major organ involvements of SLE, the outcome of inflammatory NPSLE after immunosuppressive treatment is generally good, with improvement in approximately 70% of events." @default.
• W4297374610 created "2022-09-28" @default.
• W4297374610 creator A5011195187 @default.
• W4297374610 creator A5011985687 @default.
• W4297374610 creator A5023112995 @default.
• W4297374610 creator A5035455903 @default.
• W4297374610 creator A5043742417 @default.
• W4297374610 creator A5051357297 @default.
• W4297374610 creator A5057688828 @default.
• W4297374610 creator A5065490725 @default.
• W4297374610 creator A5069559385 @default.
• W4297374610 creator A5071516046 @default.
• W4297374610 creator A5089491830 @default.
• W4297374610 date "2022-09-27" @default.
• W4297374610 modified "2023-09-26" @default.
• W4297374610 title "S14.2 Favorable outcome of patients with inflammatory neuropsychiatric lupus treated with immunosuppression" @default.
• W4297374610 doi "https://doi.org/10.1136/lupus-2022-elm2022.31" @default.
• W4297374610 hasPublicationYear "2022" @default.
• W4297374610 type Work @default.
• W4297374610 citedByCount "0" @default.
• W4297374610 crossrefType "proceedings-article" @default.
• W4297374610 hasAuthorship W4297374610A5011195187 @default.
• W4297374610 hasAuthorship W4297374610A5011985687 @default.
• W4297374610 hasAuthorship W4297374610A5023112995 @default.
• W4297374610 hasAuthorship W4297374610A5035455903 @default.
• W4297374610 hasAuthorship W4297374610A5043742417 @default.
• W4297374610 hasAuthorship W4297374610A5051357297 @default.
• W4297374610 hasAuthorship W4297374610A5057688828 @default.
• W4297374610 hasAuthorship W4297374610A5065490725 @default.
• W4297374610 hasAuthorship W4297374610A5069559385 @default.
• W4297374610 hasAuthorship W4297374610A5071516046 @default.
• W4297374610 hasAuthorship W4297374610A5089491830 @default.
• W4297374610 hasBestOaLocation W42973746101 @default.
• W4297374610 hasConcept C126322002 @default.
• W4297374610 hasConcept C2776015282 @default.
• W4297374610 hasConcept C2776912625 @default.
• W4297374610 hasConcept C2778754783 @default.
• W4297374610 hasConcept C2779134260 @default.
• W4297374610 hasConcept C2780252810 @default.
• W4297374610 hasConcept C71924100 @default.
• W4297374610 hasConceptScore W4297374610C126322002 @default.
• W4297374610 hasConceptScore W4297374610C2776015282 @default.
• W4297374610 hasConceptScore W4297374610C2776912625 @default.
• W4297374610 hasConceptScore W4297374610C2778754783 @default.
• W4297374610 hasConceptScore W4297374610C2779134260 @default.
• W4297374610 hasConceptScore W4297374610C2780252810 @default.
• W4297374610 hasConceptScore W4297374610C71924100 @default.
• W4297374610 hasLocation W42973746101 @default.
• W4297374610 hasOpenAccess W4297374610 @default.
• W4297374610 hasPrimaryLocation W42973746101 @default.
• W4297374610 hasRelatedWork W2050816940 @default.
• W4297374610 hasRelatedWork W2080757775 @default.
• W4297374610 hasRelatedWork W2122063060 @default.
• W4297374610 hasRelatedWork W2125734827 @default.
• W4297374610 hasRelatedWork W2957985297 @default.
• W4297374610 hasRelatedWork W2993463121 @default.
• W4297374610 hasRelatedWork W3010543439 @default.
• W4297374610 hasRelatedWork W3016702978 @default.
• W4297374610 hasRelatedWork W4251791110 @default.
• W4297374610 hasRelatedWork W4298836643 @default.
• W4297374610 isParatext "false" @default.
• W4297374610 isRetracted "false" @default.
• W4297374610 workType "article" @default.